Group 1 - The total IPO financing scale in the A-share market for July 2025 was 4.887 billion, with the main board raising 2.105 billion and the ChiNext board raising 2.216 billion, marking a 60% increase in the number of new stocks issued compared to the previous month [5][7][11] - As of the end of July, there were 50 IPO projects approved but not yet issued across all A-share boards, with a total proposed fundraising of 54.92 billion. The main board accounted for 40% of the proposed fundraising, while the ChiNext and Sci-Tech Innovation boards accounted for 32% and 19%, respectively [11][13] - The average winning rate for new shares in July was 0.0121% for A-class accounts and 0.0118% for B-class accounts on the main board, reflecting a decrease of 79% and 76% respectively compared to the previous month [17][23] Group 2 - The average first-day price increase for new stocks on the main board in July was 231%, while the ChiNext board saw an average increase of 119% [31][34] - In July, 3,193 funds participated in new share subscriptions, with the highest number being equity mixed funds at 1,202, followed by flexible allocation funds at 604 and passive index funds at 758 [37][39] - The contribution of new shares to funds with a scale of 1-2 billion was +0.351%, while for those with a scale of 2-3 billion, it was +0.251%, indicating a positive impact on fund performance [32][35]

Investment Rating - The report maintains an "Outperform" rating for the industry [6] Core Insights - The lithium battery sector shows an increase in production in August, with solid-state battery development accelerating [2][9] - The photovoltaic sector is undergoing energy efficiency inspections by the Ministry of Industry and Information Technology, which may lead to the elimination of outdated production capacity [3][17] - The wind power sector has seen significant growth in offshore wind capacity, positively impacting turbine bidding prices [3][27] - The energy storage sector is advancing with new regulations and a significant number of projects in progress [3][33] - The electric equipment sector is benefiting from strong performance in the data center segment and increased capital expenditures from North American CSP manufacturers [4][44] - The industrial control and robotics sector is experiencing a slight decline in PMI, but the global robotics market is expected to exceed $400 billion by 2029, with China capturing half of the market share [4][51] - The hydrogen sector is seeing the revision of industry standards and significant project signings, indicating growth potential [4][61] Summary by Sections 1. New Energy Vehicles and Lithium Battery Sector - Production in August increased, with lithium-ion battery production reaching 91.0 GWh, a 1% month-on-month increase and a 57% year-on-year increase [9] - Solid-state battery development is prioritized by leading companies, with significant orders being placed [10][11] 2. New Energy Generation Sector 2.1 Photovoltaic Sector - The Ministry of Industry and Information Technology has initiated energy efficiency inspections for 41 polysilicon companies, aiming to enhance energy efficiency and regulatory compliance [3][17] - The price of polysilicon has risen, indicating a positive market trend [19] 2.2 Wind Power Sector - Offshore wind capacity added in the first half of the year reached 2.49 GW, a 200% year-on-year increase [27] - The average utilization rate of wind power decreased to 93.2%, down 2.9 percentage points year-on-year [27] 3. Energy Storage Sector - New regulations in Shandong and Ningxia are promoting the entry of renewable energy into the market [33][34] - A total of 318 energy storage projects exceeding 124 GWh are underway across 21 regions [37] 4. Electric Equipment Sector - The company achieved a revenue of $2.638 billion in Q2 2025, a 35% year-on-year increase, driven by strong data center performance [44] - Major tech companies are increasing their capital expenditures, indicating a positive outlook for the sector [44] 5. Industrial Control and Robotics Sector - The manufacturing PMI for July was reported at 49.3%, indicating a slight decline [51] - The global robotics market is projected to exceed $400 billion by 2029, with significant contributions from Chinese manufacturers [52] 6. Hydrogen Sector - The National Energy Administration has revised 10 hydrogen industry standards, enhancing regulatory clarity [61] - A major green ammonia project with an annual production capacity of 240,000 tons has been signed, marking significant growth in the hydrogen sector [63][66]

策 华福证券 2025 年 08 月 03 日 略 研 究 策 略 定 期 报 美国有望降息且推动通胀上升的概率较高——产 业经济周观点 投资要点： 近期观点 1、 美国经济内生性下行压力较大，预计财政和货币政策有望推 动美国经济维持稳定，且通胀压力不断上升。 团队成员 分析师： 李浩(S0210524050003) lh30530@hfzq.com.cn 分析师： 李刘魁(S0210524050006) llk30550@hfzq.com.cn 相关报告 1、医疗与消费周报——古方新用与现代科技双轮 驱 动 中 药 产 业 开 启 高 质 量 发 展 新 篇 — — 2025.08.03 2、医药生物 2 主题走出主升形态——2025.08.02 3、反转策略：红利滞涨下的超额选择 —— 2025.08.02 风险提示 全球制造业复苏受阻；中美关系改善不及预期；美国地产市场不 健康 证 券 研 究 报 告 2、 中国价格复苏后，对就业呈现正面影响，对产出或有抑制， 总量层面重点是出口价格能否持续改善。 3、 供给驱动的价格复苏更有利于资产价格上升，短期价格波动 对资本市场的影响较小。 4、 重点看好非银，低 ...

Group 1 - The report maintains a strong market rating for the biopharmaceutical industry, particularly focusing on AAV gene therapy advancements in neurology and ophthalmology, highlighting companies such as Kanghong, TEBIO, and Hite [2][3][20] - AAV gene therapy has shown rapid development due to its unique properties, including small size, non-pathogenicity, and the ability to be engineered for various tissue targeting, making it a promising treatment for genetic diseases [10][11][14] - The report emphasizes the commercial success of AAV gene therapies, with notable products like Novartis' Zolgensma exceeding $1 billion in sales, indicating a growing market potential for common diseases [24][27] Group 2 - The report identifies key players in the AAV gene therapy space, including multinational corporations (MNCs) like Sanofi, Bayer, and Roche, which are actively developing pipelines targeting CNS, ophthalmology, and metabolic diseases [20][33] - It highlights the ongoing clinical trials and advancements in AAV gene therapies for common diseases, particularly in the CNS and ophthalmology sectors, with a focus on the potential of new AAV vectors to cross the blood-brain barrier [35][37] - The report suggests that domestic companies such as Kanghong, TEBIO, and Hite are well-positioned in the AAV gene therapy landscape, with diverse and rapidly progressing pipelines [42]

Market Overview - In July, the overall A-share market experienced an increase, with the CSI 300 index rising by 3.54%, the CSI 1000 by 4.80%, the CSI 500 by 5.26%, and the ChiNext by 8.14% [16][17] - The top three performing sectors in July were steel, pharmaceuticals, and telecommunications, while the banking sector saw a decline [16] Multi-Strategy Stock Selection - The multi-strategy stock selection strategy achieved an absolute return of 6.04% in July, with a relative excess return of 1.64% compared to the CSI All Share Index [30] - The strategy's weight allocation for August shows the highest allocation to growth stocks at approximately 31.03%, while the lowest allocation is to value stocks at about 15.62% [21][22] - The strategy includes four sub-strategies: value stock strategy, growth stock strategy, quality stock strategy, and liquidation stock strategy, which are adjusted based on risk parity and momentum optimization [21][30] Extreme Style High BETA Stock Selection - The extreme style high BETA stock selection strategy recorded an absolute return of 3.05% in July, with a relative excess return of -1.23% compared to the CSI All Share Index [5][19] - The weight allocation for August indicates the highest allocation to large-cap value stocks at approximately 66.86%, while the smallest allocation is to small-cap value stocks at about 33.14% [53][54] "Dividend +" Preferred Stock Strategy - The "Dividend +" preferred stock strategy achieved an absolute return of 3.70% in July, with a relative excess return of -0.60% compared to the CSI All Share Index [6][19] - The strategy's portfolio consists of 30 selected stocks, with an average market capitalization of 1,095.78 million, primarily concentrated in the power and public utilities, machinery, and transportation sectors [6] Moving Average Trend Strategy - The moving average trend strategy recorded an absolute return of 5.07% in July, with a relative excess return of 0.71% compared to the CSI All Share Index [7][19] - The strategy's portfolio includes 30 stocks, mainly distributed across the non-ferrous metals, telecommunications, and steel industries [7] Sentiment Price-Volume Strategy - The sentiment price-volume strategy's top 50 combination achieved an absolute return of 7.68% in July, with a relative excess return of 3.21% compared to the CSI All Share Index [8][19] - The strategy's portfolio consists of 50 selected stocks, primarily in the electronics, machinery, and automotive sectors [8] Sci-Tech Innovation Board Strategy - The Sci-Tech Innovation Board strategy achieved an absolute return of 14.11% in July, with a relative excess return of 9.27% compared to the ChiNext 50 Index [8][19] - The strategy's portfolio includes 30 selected stocks, with nearly 40% concentrated in the pharmaceutical industry [8]

行 业 研 究 华福证券 汽车 2025 年 08 月 03 日 低空行业周报（7 月第 5 周）：深圳发布低空基 础设施高质量建设方案，行业静待催化 投资要点： 本周行情回顾 行 业 定 期 报 本周（7 月 28-8 月 1 日）Wind 低空经济指数下跌 0.11%，概念板 块排名 114/330，整体跑赢大盘（上证指数本周下跌 0.57%）。与其他 科技条线主题板块相比，跑赢人形机器人指数 2.05pct，跑输 AI 算力指 数 0.59pct。 本周上证指数在前半周创本年新高后，后半周有所回调，低空经 济指数本周整体走势与大盘相仿。标的走势相对分化，莱斯信息等基 础设施建设相关的标的本周走势相对较好；此外我们此前建议关注的 新标的腾亚精工本周上涨 19%，属于在低空赛道中充分走出超额收益 的标的。本周深圳市发布《深圳市低空基础设施高质量建设方案（2024 —2026 年）》，后续其他地区也有望逐步推进基础设施相关的方案文 件，低空经济产业落地正逐步推进。 华福证券 证 券 研 究 报 告 整体而言，当前位置合适+下半年以来催化不断+中美新博弈方向， 低空是具备反弹要素的。1）开年以来除了年初一小波行 ...

Investment Rating - The industry rating is "Outperform the Market" [8] Core Insights - The establishment of China Changan Automobile Group on July 29, 2025, with a registered capital of 20 billion yuan and total assets of 308.7 billion yuan, marks a significant step in optimizing state-owned capital layout and enhancing the competitiveness of China's automotive industry [3][14] - The launch of the Li Auto i8, a mid-large pure electric SUV priced between 321,800 to 369,800 yuan, features a range of 720 km and a fast charging capability of 500 km in just 10 minutes [4][15] - The launch of the Leidao L90, a large pure electric SUV priced between 265,800 to 299,800 yuan, is based on NIO's NT3.0 platform and supports a 900V high-voltage architecture [4][17] Market Performance - From July 28 to August 1, 2025, the automotive sector declined by 2.4%, underperforming the CSI 300 index, which fell by 1.8% [20] - Year-to-date, the automotive sector has increased by 9.8%, ranking 15th among 31 sectors [20] Sales Data - From July 1 to 27, 2025, retail sales of passenger vehicles reached 1.445 million units, a year-on-year increase of 9%, but a month-on-month decrease of 19% [6][38] - New energy passenger vehicle retail sales during the same period were 789,000 units, up 15% year-on-year but down 17% month-on-month [6][39] Key New Vehicles - The Li Auto i8 and Leidao L90 are highlighted as significant new electric vehicle launches, with the i8 focusing on family usability and the L90 offering advanced features and spaciousness [15][17][81]

Investment Rating - The report maintains an "Outperform" rating for the industry [7] Core Insights - The domestic CD7 CAR-T therapy is expected to achieve breakthroughs, with a focus on Anke Biopharma [5][17] - The market for innovative drugs continues to show strong performance, with significant trading volume and interest in new drug developments [5][41] Market Review - The CITIC Pharmaceutical Index rose by 2.7% during the week of July 28 to August 1, 2025, outperforming the CSI 300 Index by 4.5 percentage points, ranking second among CITIC's primary industry classifications [4][41] - Year-to-date, the CITIC Pharmaceutical and Biotech Index has increased by 22.8%, surpassing the CSI 300 Index by 19.7 percentage points [4][41] - The top five performing stocks for the week included Nanjing New Drug (up 78%), Lide Man (up 46.4%), Chenxin Pharmaceutical (up 40.9%), Qizheng Tibetan Medicine (up 40%), and Guangshengtang (up 36.4%) [4][56] Focus on CD7 CAR-T Therapy - Relapsed/refractory T-ALL/LBL has a poor prognosis, with a median survival of only 6 months and limited treatment options available [5][17][18] - Anke Biopharma's PA3-17 is leading in domestic clinical trials for CD7 CAR-T therapy, currently in Phase II, showing an overall response rate (ORR) of 84.6% and a complete response (CR) rate of 76.9% in Phase I trials [5][27][26] - The potential for PA3-17 to become the first approved product targeting T-cell malignancies in China is significant, with opportunities for expanding indications [5][26][33] Investment Recommendations - The report suggests focusing on a combination of innovative drugs, particularly those with commercial capabilities and rich pipelines, as well as medical devices that are expected to see a turnaround in fundamentals [5][41] - Recommended stocks for August include Heng Rui Pharmaceutical, Kangfang Biopharma, Kanghong Pharmaceutical, and others [5][12]

Core Insights - The report highlights the positive performance of the pharmaceutical index, with five out of six sub-industries recording positive returns this week [2] - The approval of the traditional Chinese medicine "Loquat Lung Clearing Granules," developed by Xiamen University and Shenwei Pharmaceutical, marks a significant achievement in the modernization of traditional medicine, showcasing the integration of ancient wisdom with modern technology [3][8] - The Chinese traditional medicine industry is entering a new phase of high-quality development, supported by government policies and technological innovations, with the market size expected to exceed 480 billion yuan by 2024 [9][10] Industry Performance Review - The pharmaceutical sector, particularly the chemical pharmaceuticals and traditional Chinese medicine sub-industries, showed strong performance with increases of 5.01% and 3.12% respectively [14] - The valuation levels for the chemical pharmaceuticals and biological products were the highest at 92.95 times and 74.63 times respectively, while traditional Chinese medicine had a valuation of 34.05 times [14] Industry Trends and Developments - The report discusses the implementation of the "Strong Foundation Project" by the National Development and Reform Commission, aimed at enhancing grassroots healthcare services and promoting the integration of traditional Chinese medicine into the healthcare system [21] - The introduction of policies in Henan Province to include suitable traditional Chinese medicine techniques in medical insurance coverage is expected to alleviate the economic burden on patients and promote the use of traditional medicine in chronic disease treatment [26][30]

Investment Rating - The report maintains an "Outperform" rating for the industry [8] Core Insights - The introduction of the "flow tax" is expected to improve the competitive landscape and profitability of sectors such as clean appliances, pet food, and kitchen small appliances [12][14] - The newly announced childcare subsidy policy will provide 3,600 yuan per year for each newborn until the age of three, which is anticipated to lower family birth costs and stimulate demand in the maternal and infant sectors [15][18] - The report highlights that the domestic demand is expected to recover due to policy support, with specific recommendations for major appliance companies benefiting from trade-in programs [19] Summary by Sections Investment Opportunities - The "flow tax" regulation limits tax deductions for advertising expenses to 15% of annual revenue, which may lead to a more sustainable competitive environment in e-commerce [12][14] - The childcare subsidy program is projected to create a market of approximately 100 billion yuan annually, benefiting maternal and infant products [15][18] Weekly Market Insights - The home appliance sector experienced a decline of 2.3% this week, with specific segments like white goods and kitchen appliances seeing drops of 2.6% and 3.2% respectively [24] - The textile and apparel sector also faced a decline of 2.14%, with cotton prices showing a decrease of 1.86% [26] Investment Recommendations - Major appliance companies such as Midea Group, Haier Smart Home, and Gree Electric are recommended due to expected benefits from trade-in policies [19] - The pet industry is highlighted as a resilient sector, with companies like Guibao Pet and Zhongchong Co. suggested for investment [19] - Small appliances and branded apparel are expected to see a recovery in demand, with recommendations for leading brands like Supor and Anta Sports [19] Global Expansion Themes - The report emphasizes the long-term theme of overseas expansion, recommending leading clean appliance brands like Roborock and Ecovacs for their global market potential [20] - The report also notes that Chinese manufacturers maintain a competitive edge in global markets, particularly in major appliances and tools [20]